The Head of State Sheikh Mohammed bin Zayed Al Nahyan attended some of the “Group of 77 and China” meetings held during the proceedings of the Conference of the Parties to the United Nations. Framework Conference on Climate Change (COP28), which is taking place at Expo City Dubai.

While attending the meeting, he welcomed the participating leaders and emphasized the importance of cooperation among developing countries to promote their common interests and to ensure their presence in international affairs, embodied in the meetings of the group.

His Highness emphasized the UAE’s interest in strengthening international cooperation to achieve the success of the goals of the 28th session of the Conference of the Parties in accelerating the transition towards a sustainable, low-carbon, high-growth economic model through effective detection. Action-based solutions to the climate crisis facing the world.

For their part, participants appreciated the UAE’s hosting of the first-ever group meetings at COP conferences, noting that the meetings provided an opportunity to discuss areas of common interest, identify common challenges and propose measures to address them. Confront team members while emphasizing the importance of teamwork and cooperation.

During the World Climate Action Summit, the leaders also appreciated the announcement of the President of the State, emphasizing the importance of this initiative in supporting the path of sustainable development and promoting sustainable development globally. Based on international cooperation.

They also emphasized the importance of the “COP28” agenda, which aims to catalyze collective action to protect ecosystems and food systems that are resilient to climate change, empowering the most affected communities by investing in practical solutions to improve lives and livelihoods. .

Muhammad bin Saeed:

• Finding effective solutions to the global climate crisis.

• Accelerating the transition towards a sustainable economic model.

United Arab Emirates (CNN) — Kuwaiti Emir Sheikh Nawaf Al-Ahmad Al-Jaber Al-Sabah’s health condition was confirmed on Saturday by the Minister of Emirati Diwan Affairs, Sheikh Muhammad Al-Abdullah Al-Sabah. It is stable, thanks to God Almighty,” Kuwait News Agency reported. “Kona.”

The minister added: “We pray to the Almighty God for a speedy recovery to the Emir of the country and to grant him good health and complete well-being.”

The Minister of Amiri Diwan Affairs said on Wednesday that the health of the Emir of Kuwait is stable and he is still receiving the necessary treatment.

Earlier, the Amiri Diwan minister said the Kuwaiti emir “entered the hospital to receive treatment and undergo a medical examination following a health condition”.

For its part, the Kuwaiti Public Prosecution warned in a statement on Saturday against “taking decisive action and filing criminal charges against every individual, group, platform, media, radio station or any organization that publishes or addresses anything related to the health of the Emir or the arrangement of the ruling house.”

The Kuwait Public Prosecution added: “We have been monitoring many false reports and shocking lies in the media, and by individuals on visual, audio and print media platforms, about the health of the Emir of the country or the arrangements of the ruling house. According to Kuna.

Rumor mongers have used the word as a weapon to spread poison in the society using flimsy pretexts of freedom of expression, good intentions and fear, forgetting the harmful effects of rumours. According to the Kuwaiti Agency, there is more than a raging plague.

However, Pfizer announced its intention to develop a modified version of the drug “Danoglipron”.

This drug belongs to a new class of successful treatments based on a component such as the gastrointestinal hormone glucagon or GLP-1 (GLP-1).GLP-1This leads to a feeling of fullness and weight loss.

“Danoglibron” differs from competing drugs already on the market in that it is not given by injection, but is given orally in the form of tablets.

During the clinical trial, Pfizer tested taking these pills twice a day, but said it wanted to focus on a new once-a-day formulation.

The clinical trial included a few hundred obese participants without type 2 diabetes.

Pfizer explained that the side effects in this trial were similar to those that can occur with this type of drug, but “it is noteworthy that their rates were high” because “cases of nausea reached 73 percent, vomiting reached 47 percent, and diarrhea reached 25 percent.”

More than half of the participants who received this drug discontinued treatment.

However, “Danoglipro” has been shown to lead to weight loss between 8 percent and 13 percent over 32 weeks or between 5 percent and 9.5 percent over 26 weeks.

A report quoted Pfizer senior executive Michael Tolston as confirming that “an improved once-daily formulation of tanoglipron could play an important role in the treatment of obesity.”

The highly lucrative anti-obesity drug market is currently dominated by the Danish “Novo Nordisk” group with its drug “Vecovi” and the American “Eli Lilly” company “Zebound”. America last month.